Movement Alert|Axsome Therapeutics Intraday Decline 5.27%, Post-Earnings Pullback Continues After Target Price Cut

Market Focus11-06

On November 6, Axsome Therapeutics fell 5.27% in Regular Trading, trading at $129.83 per share, with turnover of $83.65 million.

The latest market backdrop points to a post-earnings reassessment after the company reported third-quarter results above expectations, while RBC Capital Markets lowered its price target to $273 from $295 and maintained an outperform rating.

Axsome Therapeutics reported a third-quarter loss of $0.25 per share, better than consensus estimates of roughly $0.56 to $0.63, while revenue rose to $259.7 million from $171.0 million a year earlier and exceeded expectations near $249 million. Net product sales of Auvelity reached $207.6 million. Recent market commentary also noted that investors are re-evaluating upside after the earnings-driven rally, even as the firm said Axsome could reach profitability in 2027 if Auvelity revenue continues to expand.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment